ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016
Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review.Neuropsychology review · 2025Pooled it
- A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigue.Cell reports. Medicine · 2025Trial
- Cancer‑related fatigue during combined treatment of androgen deprivation therapy and radiotherapy is associated with mitochondrial dysfunction.International journal of molecular medicine · 2020Trial
- Trial
- Muscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy.Nature communications · 2026Article
- Rehabilitation intervention to prevent adverse events related to ADT in patients with metastatic prostate cancer.Future science OA · 2025Article
- Article
- The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue.Frontiers in oncology · 2024Article
- Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.Medicina (Kaunas, Lithuania) · 2023Review
- Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide.JMA journal · 2022Article
- Article
- Fatigue prevalence in men treated for prostate cancer: A systematic review and meta-analysis.World journal of clinical cases · 2021Article
- Article
- Beetroot as a Potential Functional Food for Cancer Chemoprevention, a Narrative Review.Journal of cancer prevention · 2021Review
- Steroid Hormone Biosynthesis Metabolism Is Associated With Fatigue Related to Androgen Deprivation Therapy for Prostate Cancer.Frontiers in cell and developmental biology · 2021Article
- Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers.Current oncology reports · 2020Review
- Cancer-Related Fatigue: Causes and Current Treatment Options.Current treatment options in oncology · 2020Review
- Physical activity and associations with treatment-induced adverse effects among prostate cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Article
- Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis.American journal of translational research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeAlthough fatigue is a common problem for men with prostate cancer undergoing androgen deprivation therapy (ADT), there has been little systematic research on this issue. The present study examined changes in fatigue among prostate cancer patients receiving ADT compared to controls and predictors of heightened fatigue in ADT patients.
methodsProstate cancer patients treated with ADT (ADT+ group, n = 60) completed assessments of fatigue prior to or just after ADT initiation (baseline) and 6 and 12 months later. Prostate cancer patients treated with prostatectomy only (ADT- group, n = 85) and men without cancer (CA- group, n = 86) matched on age and education completed assessments at similar intervals.
resultsGroup-by-time interactions for fatigue severity, interference, and duration were observed when comparing the ADT+ group to the controls. Groups did not differ at baseline; however, the ADT+ group reported worse fatigue at 6 and 12 months. The same pattern was observed for changes in the prevalence of clinically meaningful fatigue and the extent of clinically meaningful change in fatigue. Within the ADT+ group, higher baseline comorbidity scores were associated with greater increases in fatigue interference, and higher baseline Gleason scores were associated with greater increases in fatigue duration.
conclusionsProstate cancer patients receiving ADT demonstrate a trajectory of worsened fatigue during the first 12 months following treatment initiation relative to the controls. Greater comorbidities and higher Gleason scores at baseline appear to be risk factors for heightened fatigue during the first year following ADT initiation. Results highlight important time points for implementation of interventions aimed at fatigue reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.